Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy

References

• DöhnerHEsteyEHAmadoriSDiagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNetBlood2010115345347419880497
   PubMed Web of Science ®Google Scholar
• SchlenkRFDöhnerKKrauterJMutations and treatment outcome in cytogenetically normal acute myeloid leukemiaN Engl J Med2008358181909191818450602
   PubMed Web of Science ®Google Scholar
• MarcucciGHaferlachTDöhnerHMolecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implicationsJ Clin Oncol201129547548621220609
   PubMed Web of Science ®Google Scholar
• EsteyEDöhnerHAcute myeloid leukaemiaLancet200636895501894190717126723
   PubMed Web of Science ®Google Scholar
• RubnitzJEGibsonBSmithFOAcute myeloid leukemiaPediatr Clin North Am2008551215118242314
   PubMedGoogle Scholar
• FerraraFUnanswered questions in acute myeloid leukaemiaLancet Oncol20045744345015231251
   PubMed Web of Science ®Google Scholar
• LeyTJMillerCDingLCancer Genome Atlas Research NetworkGenomic and epigenomic landscapes of adult de novo acute myeloid leukemiaN Engl J Med2013368222059207423634996
   PubMed Web of Science ®Google Scholar
• IshikawaYKiyoiHTsujimuraAComprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemiaEur J Haematol2009832909819309322
   PubMedGoogle Scholar
• KindlerTLipkaDBFischerTFLT3 as a therapeutic target in AML: still challenging after all these yearsBlood2010116245089510220705759
   PubMed Web of Science ®Google Scholar
• WeisbergESattlerMRayAGriffinJDDrug resistance in mutant FLT3-positive AMLOncogene201029375120513420622902
   PubMedGoogle Scholar
• SmithCCWangQChinCSValidation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemiaNature2012485739726026322504184
   PubMed Web of Science ®Google Scholar
• SatoTYangXKnapperSFLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivoBlood2011117123286329321263155
   PubMed Web of Science ®Google Scholar
• LevisMRavandiFWangESResults from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapseBlood2011117123294330121270442
   PubMed Web of Science ®Google Scholar
• BhullarJNatarajanKShuklaSThe FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactionsPLoS One201388e7126623967177
   PubMedGoogle Scholar
• ServeHKrugUWagnerRSorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trialJ Clin Oncol201331253110311823897964
   PubMed Web of Science ®Google Scholar
• WidemannBCKimAFoxEA phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children’s Oncology Group Phase I Consortium reportClin Cancer Res201218216011602222962440
   PubMed Web of Science ®Google Scholar
• HuRYongKTRoyIDingHHeSPrasadPNMetallic nanostructures as localized plasmon resonance enhanced scattering probes for multiplex dark field targeted imaging of cancer cellsJ Phys Chem C Nanomater Interfaces200911372676268420046993
   PubMedGoogle Scholar
• PotaraMBocaSLicareteEChitosan-coated triangular silver nanoparticles as a novel class of biocompatible, highly sensitive plasmonic platforms for intracellular SERS sensing and imagingNanoscale20135136013602223715524
   PubMed Web of Science ®Google Scholar
• Boca-FarcauSPotaraMSimonTJuhemABaldeckPAstileanSFolic acid-conjugated, SERS-labeled silver nanotriangles for multimodal detection and targeted photothermal treatment on human ovarian cancer cellsMol Pharm201411239139924304361
   PubMedGoogle Scholar
• MarkmanJLRekechenetskiyAHollerELjubimovaJYNanomedicine therapeutic approaches to overcome cancer drug resistanceAdv Drug Deliv Rev2013651866187924120656
   PubMed Web of Science ®Google Scholar
• BiskerGYeheskely-HayonDMinaiLYelinDControlled release of Rituximab from gold nanoparticles for phototherapy of malignant cellsJ Control Release201216230330922759981
   PubMed Web of Science ®Google Scholar
• OrzaASoriţăuOTomuleasaCReversing chemoresistance of malignant glioma stem cells using gold nanoparticlesInt J Nanomedicine2013868970223467447
   PubMed Web of Science ®Google Scholar
• TomuleasaCSoritauOOrzaAGold nanoparticles conjugated with cisplatin/doxorubicin/capecitabine lower the chemoresistance of hepatocellular carcinoma-derived cancer cellsJ Gastrointestin Liver Dis201221218719622720309
   PubMed Web of Science ®Google Scholar
• PetrushevBTomuleasaCSoritauOMetformin plus PIAF combination chemotherapy for hepatocellular carcinomaExp Oncol2012341172422453143
   PubMedGoogle Scholar
• MiklášováNFischer-FodorELönneckePAntiproliferative effect of novel platinum(II) and palladium(II) complexes on hepatic tumor stem cells in vitroEur J Med Chem201249414722305340
   PubMed Web of Science ®Google Scholar
• QuentmeierHMartelliMPDirksWGCell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosminLeukemia200519101760176716079892
   PubMedGoogle Scholar
• TsuchiyaSYamabeMYamaguchiYKobayashiYKonnoTTadaKEstablishment and characterization of a human acute monocytic leukemia cell line (THP-1)Int J Cancer19802621711766970727
   PubMed Web of Science ®Google Scholar
• LiLMasicaDIshidaMHuman bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosisHepatology201460389690724497320
   PubMed Web of Science ®Google Scholar
• FloreaACraciunCBee venom induced in vivo ultrastructural reactions of cells involved in the bone marrow erythropoiesis and of circulating red blood cellsMicrosc Microanal201319239340523375112
   PubMedGoogle Scholar
• TomuleasaCIForisVSoriţăuOEffects of 60Co gamma-rays on human osteoprogenitor cellsRom J Morphol Embryol200950334935519690759
   PubMed Web of Science ®Google Scholar
• SoriţăuOTomuleasaCIPállEEnhanced chemoresistance and tumor sphere formation as a laboratory model for peritoneal micrometastasis in epithelial ovarian cancerRom J Morphol Embryol201051225926420495740
   PubMedGoogle Scholar
• TomuleasaCSoritauOBrieIMesenchymal stem cell irradiation in culture engages differential effect of hyper-fractionated radiotherapy for head and neck cancersJ BUON201015234835620658734
   PubMed Web of Science ®Google Scholar
• TomuleasaCSoritauOKacsoGArsenic trioxide sensitizes cancer stem cells to chemoradiotherapy. A new approach in the treatment of inoperable glioblastoma multiformeJ BUON201015458762
   Google Scholar
• TomuleasaCSoritauOFischer-FodorEArsenic trioxide plus cisplatin/interferon α-2b/doxorubicin/capecitabine combination chemotherapy for unresectable hepatocellular carcinomaHematol Oncol Stem Cell Ther201142606621727766
   PubMedGoogle Scholar
• SoritauOTomuleasaCAldeaMMetformin plus temozolomide-based chemotherapy as adjuvant treatment for WHO grade III and IV malignant gliomasJ BUON201116228228921766499
   PubMedGoogle Scholar
• PengHIshidaMLiLPseudogene INTS6P1 regulates its cognate gene INTS6 through competitive binding of miR-17-5p in hepatocellular carcinomaOncotarget2015685666567725686840
   PubMedGoogle Scholar
• LiLZhouLLiYLinSTomuleasaCMicroRNA-21 stimulates gastric cancer growth and invasion by inhibiting the tumor suppressor effects of programmed cell death protein 4 and phosphatase and tensin homologJ BUON201419122823624659669
   PubMed Web of Science ®Google Scholar
• YamanakaSOlaruAVAnFMicroRNA-21 inhibits Serpini1, a gene with novel tumour suppressive effects in gastric cancerDig Liver Dis201244758959622464652
   PubMedGoogle Scholar
• VerstraeteKVandriesscheGJanuarMStructural insights into the extracellular assembly of the hematopoietic Flt3 signaling complexBlood20111181606821389326
   PubMed Web of Science ®Google Scholar
• ZhangWKonoplevaMShiYXMutant FLT3: a direct target of sorafenib in acute myelogenous leukemiaJ Natl Cancer Inst2008100318419818230792
   PubMed Web of Science ®Google Scholar
• CucuianuADominant and opportunistic leukemic clones: proposal for a pathogenesis-oriented classification in acute myeloid leukemiaMed Hypotheses200565110711315893127
   PubMedGoogle Scholar
• CucuianuAChaos in cancer?Nat Med1998412134213439846552
   PubMedGoogle Scholar
• OpatzSPolzerHHeroldTExome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemiaBlood2013122101761176923878140
   PubMed Web of Science ®Google Scholar
• KellyLMGillilandDGGenetics of myeloid leukemiasAnnu Rev Genomics Hum Genet2002317919812194988
   PubMed Web of Science ®Google Scholar
• WelchJSLeyTJLinkDCThe origin and evolution of mutations in acute myeloid leukemiaCell2012150226427822817890
   PubMed Web of Science ®Google Scholar
• DingLLeyTJLarsonDEClonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencingNature2012481738250651022237025
   PubMed Web of Science ®Google Scholar
• HayakawaFTowatariMKiyoiHTandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell linesOncogene200019562463110698507
   PubMed Web of Science ®Google Scholar
• MizukiMFenskiRHalfterHFlt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathwaysBlood200096123907391411090077
   PubMed Web of Science ®Google Scholar
• DrukerBJTalpazMRestaDJEfficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemiaN Engl J Med2001344141031103711287972
   PubMed Web of Science ®Google Scholar
• FernandezHFSunZYaoXAnthracycline dose intensification in acute myeloid leukemiaN Engl J Med2009361131249125919776406
   PubMed Web of Science ®Google Scholar
• SmithBDLevisMBeranMSingle-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemiaBlood2004103103669367614726387
   PubMed Web of Science ®Google Scholar
• CortesJEKantarjianHForanJMPhase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication statusJ Clin Oncol201331293681368724002496
   PubMed Web of Science ®Google Scholar
• ZarrinkarPPGunawardaneRNCramerMDAC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)Blood2009114142984299219654408
   PubMed Web of Science ®Google Scholar
• De ZernAESungAKimSRole of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institutionBiol Blood Marrow Transplant20111791404140921324374
   PubMedGoogle Scholar
• RavandiFCortesJEJonesDPhase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemiaJ Clin Oncol201028111856186220212254
   PubMed Web of Science ®Google Scholar
• SasineJPSchillerGJEmerging strategies for high-risk and relapsed/refractory acute myeloid leukemia: novel agents and approaches currently in clinical trialsBlood Rev20152911925441922
   PubMedGoogle Scholar
• SmithCCShahNPThe role of kinase inhibitors in the treatment of patients with acute myeloid leukemiaAm Soc Clin Oncol Educ Book201331331823714533
   PubMedGoogle Scholar
• PortMBöttcherMTholFPrognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysisAnn Hematol20149381279128624801015
   PubMed Web of Science ®Google Scholar
• MeyerSCLevineRLTranslational implications of somatic genomics in acute myeloid leukaemiaLancet Oncol2014159e382e39425079101
   PubMedGoogle Scholar